Work

Study of JAK inhibition in stem-like prostate cancer (JASPER): A phase 1/2 multicenter study of ruxolitinib and enzalutamide in castration resistant prostate cancer undergoing lineage plasticity.

Year: 2025

Type: article

Study design: Study Protocol

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.5_suppl.tps297

Authors: Thomas Christopher Westbrook, Frank Cameron Cackowski, Joshi J. Alumkal, Anbarasu Kumaraswamy, Megan Veresh Caram, Sarah Elizabeth Yentz, Ulka N. Vaishampayan, Manjunath Pai, Thomas Braun, Zachery R Reichert

Institutions: Rush University Medical Center, Wayne State University, The Barbara Ann Karmanos Cancer Institute, University of Michigan, U-M Rogel Cancer Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Incyte

OpenAlex ID: W4407701903

FWCI: 0.608

Cites:

Cited by: 1

Related to: 10